chemieunternehmen.com

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC („Cyprotex“, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-its-intent-to-acquire-cyprotex-plc-5404

Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-cns-pharmacology-agreement-5402

Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-carrick-therapeutics-build-strategic-alliance-5398

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-further-important-pre-clinical-milestone-in-endometriosis-alliance-with-bayer-5396

Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc („C4XD“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-strategic-multi-target-alliance-with-c4x-discovery-5394

Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research („Inserm“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-a-research-collaboration-with-inserm-in-oncology-5392

Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-partner-to-develop-new-treatments-to-fight-kidney-diseases-5387

Evotec AG today reported financial results and corporate updates for the first half of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2016-5384